Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Avalo Therapeutics, Inc. reported that Chief Legal Officer Paul Varki received a grant of stock options covering 80,000 shares on February 26, 2026. The options have an exercise price of $0.00 per share, reflecting a compensatory award rather than a market purchase.
According to the vesting terms, 25% of the option grant will vest on February 26, 2027, with the remaining 75% vesting in equal monthly installments over the following three years. Vesting is conditioned on Varki's continued service with the company on each applicable vesting date.
Avalo Therapeutics reported that Chief Strategy Officer Jennifer Riley received a grant of stock options giving her the right to buy 95,000 shares of common stock. The award was reported at a price of $0.00 per share, reflecting a compensatory option grant rather than an open-market trade.
According to the disclosure, the option vests 25% on February 26, 2027, with the remaining shares vesting in equal monthly installments over the following three years, as long as she continues in service on each vesting date. This filing shows an increase in her derivative equity holdings through a grant/award acquisition, not a sale of existing shares.
Avalo Therapeutics, Inc. disclosed that Chief Medical Officer Mittie Doyle received a grant of stock options for 105,000 shares on February 26, 2026. The option has an exercise price reported as $0.0000 per share. Twenty‑five percent vests on February 26, 2027, with the remaining options vesting in equal monthly installments over the following three years, conditioned on continued service.
Boyd Taylor reported acquisition or exercise transactions in this Form 4 filing.
Avalo Therapeutics, Inc. reported that its Chief Business Officer, Boyd Taylor, received a grant of stock options covering 95,000 shares. The options were awarded as a derivative security and are held directly.
The award vests 25% on February 26, 2027, with the remaining options vesting in equal monthly installments over the following three years, subject to Boyd Taylor’s continued service on each vesting date.
Sullivan Christopher Ryan reported acquisition or exercise transactions in this Form 4 filing.
Avalo Therapeutics reported that its Chief Financial Officer, Christopher Ryan Sullivan, received a grant of stock options representing 105,000 shares of common stock. These options were awarded on February 26, 2026 as an equity-based compensation grant.
The stock option vests 25% on February 26, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, conditioned on his continued service. After this grant, Sullivan held 105,000 stock options directly.
NEIL GARRY ARTHUR reported acquisition or exercise transactions in this Form 4 filing.
Avalo Therapeutics, Inc. reported that Chief Executive Officer Neil Garry Arthur received a grant of stock options covering 286,000 shares on February 26, 2026. The option vests 25% on February 26, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, subject to his continued service.
Avalo Therapeutics disclosed that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported shared beneficial ownership of 934,429 shares of common stock, representing 5.0% of the class.
The holdings are reported under a joint filing agreement dated 02/23/2026; voting and dispositive power are shown as shared among the filers.
OrbiMed Advisors LLC filed an amended Schedule 13G stating beneficial ownership of 1,187,300 shares of Avalo Therapeutics common stock, representing 6.4% of the class as of December 31, 2025.
OrbiMed reports zero sole voting or dispositive power and shared voting and dispositive power over all 1,187,300 shares, held on behalf of other persons entitled to dividends or sale proceeds. The firm certifies the position was not acquired to change or influence control of Avalo Therapeutics.
Avalo Therapeutics, Inc. received an updated ownership report from Caligan Partners LP and David Johnson. They report beneficial ownership of 881,533 shares of Avalo common stock, representing 4.9% of the outstanding shares, based on 18,133,968 shares outstanding as of November 3, 2025.
The shares are held through Caligan-managed funds and accounts, with shared voting and dispositive power over all reported shares. The reporting persons state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Avalo Therapeutics.
Point72 Asset Management and related entities report beneficial ownership of 627,502 shares of Avalo Therapeutics common stock, representing 3.5% of the class as of December 31, 2025. The stake is held through an investment fund managed by Point72, with no shares owned directly by the reporting persons.
Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen each report shared voting and dispositive power over these shares and no sole voting or dispositive power. They certify the investment is not for the purpose of changing or influencing control of Avalo Therapeutics.